Your browser doesn't support javascript.
loading
Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
Samadzadeh, Sara; Olesen, Mads Nikolaj; Wirenfeldt, Martin; Möller, Sören; Misu, Tatsuro; Soelberg, Kerstin; Frederiksen, Jette Lautrup; Heegaard, Steffen; Mariotto, Sara; Fujihara, Kazuo; Ruprecht, Klemens; Andersen, Thomas Levin; Marignier, Romain; Lillevang, Søren Thue; Flanagan, Eoin P; Pittock, Sean J; Kim, Ho Jin; Bennett, Jeffrey L; Paul, Friedemann; Sorensen, Grith Lykke; Weinshenker, Brian G; Lassmann, Hans; Asgari, Nasrin.
Afiliação
  • Samadzadeh S; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Olesen MN; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Wirenfeldt M; Department of Neurology, Slagelse Hospital, Slagelse, Denmark/Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Möller S; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Misu T; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Soelberg K; Department of Neurology, Slagelse Hospital, Slagelse, Denmark/Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
  • Frederiksen JL; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Heegaard S; Department of Pathological Anatomy and Molecular Biology, Hospital South West Jutland, Esbjerg, Denmark.
  • Mariotto S; Open Patient Data Explorative Network, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Fujihara K; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Ruprecht K; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Andersen TL; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark.
  • Marignier R; Departments of Ophthalmology and Pathology, Rigshospitalet, Glostrup, Denmark.
  • Lillevang ST; Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
  • Flanagan EP; Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Pittock SJ; Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan.
  • Kim HJ; Department of Neurology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Bennett JL; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Paul F; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Sorensen GL; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Weinshenker BG; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
  • Lassmann H; Department Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
  • Asgari N; Department Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Mult Scler ; 29(14): 1721-1735, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37830484
ABSTRACT

BACKGROUND:

Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the human central nervous system (CNS).

OBJECTIVES:

We determined MFAP4 CNS expression and measured cerebrospinal fluid (CSF) and serum levels.

METHODS:

Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) (n = 3), progressive MS (n = 3), neuromyelitis optica spectrum disorder (NMOSD) (n = 2), and controls (n = 9), including 6 healthy controls (HC). MFAP4 levels were measured in 152 patients 49 MS, 62 NMOSD, 22 myelin oligodendrocyte glycoprotein-associated disease (MOGAD), and 19 isolated optic neuritis (ION).

RESULTS:

MFAP4 localized to meninges and vascular/perivascular spaces, intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and less in progressive MS. CSF MFAP4 levels were reduced during relapse and at the onset of diseases (mean U/mL MS 14.3, MOGAD 9.7, and ION 14.6 relative to HC 17.9. (p = 0.013, p = 0.000, and p = 0.019, respectively). Patients with acute ON (n = 68) had reduced CSF MFAP4 (mean U/mL 14.5, p = 0.006). CSF MFAP4 levels correlated negatively with relapse severity (rho = -0.41, p = 0.017).

CONCLUSION:

MFAP4 immunoreactivity was reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following relapse and may reflect disease activity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuromielite Óptica / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuromielite Óptica / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Idioma: En Ano de publicação: 2023 Tipo de documento: Article